European Commission suspects pharma group Teva broke antitrust rules
PARIS (Reuters) – The European Commission has informed Teva Pharmaceutical of its preliminary view that the company breached European Union (EU) antitrust rules with practices aimed at delaying competition to multiple sclerosis product Copaxone. The Commission first carried out unannounced inspections at the premises of several Teva subsidiaries in October 2019 and in March 2021 …
European Commission suspects pharma group Teva broke antitrust rules Read More »










